Patents Issued in February 22, 2018
  • Publication number: 20180051061
    Abstract: Antimicrobial peptides and methods of use are provided.
    Type: Application
    Filed: August 18, 2017
    Publication date: February 22, 2018
    Inventor: Guangshun Wang
  • Publication number: 20180051062
    Abstract: Improved casein-based films are produced by adjusting the pH of a film-production suspension. The film-production suspension may contain a casein source, a plasticizer, and optionally a strengthening additive. The adjustment of the pH may be accomplished by the addition of an alkaline additive, such as a base, to achieve a desired pH value. The improved casein-based films have improved physical properties as compared to those produced without a pH-adjusted film-production suspension at least in part due to the chemical and structural changes imparted by the change in pH.
    Type: Application
    Filed: August 17, 2017
    Publication date: February 22, 2018
    Inventors: LAETITIA BONNAILLIE, Peggy M. Tomasula
  • Publication number: 20180051063
    Abstract: The present invention concerns an improved therapeutic regimen for GHD therapy. In particular, the invention concerns methods for bolus dose administration of a human growth hormone-XTEN (hGH-XTEN) fusion protein.
    Type: Application
    Filed: July 13, 2017
    Publication date: February 22, 2018
    Inventors: Jeffrey L. Cleland, George M. Bright, Eric Humphriss, Volker Schellenberger, Joshua Silverman, Willem P. Stemmer, Chia-Wei Wang, Nathan Greething, Benjamin Spink
  • Publication number: 20180051064
    Abstract: A peptide that binds specifically to neuropilin-1 (NRP1) without binding to neuropilin-2 (NRP2) is provided. A fusion protein, a fusion antibody, small-molecule drug, a nanoparticle, or a liposome, which comprises the peptide, and a pharmaceutical composition for treating or preventing cancer or angiogenesis-related diseases, and a composition for diagnosing cancer or angiogenesis-related diseases are provided. A polynucleotide encoding the peptide that binds specifically to NRP1 and a method for screening the peptide that binds specifically to NRP1 are provided. An antibody heavy-chain constant region Fc-fused peptide binding specifically to NRP1 has the property of binding specifically to NRP1, and thus when it is administered in vivo, it accumulates selectively in tumor tissue, and widens the intercellular space between tumor-associated endothelial cells to promote its extravasation and increases its tumor tissue penetration.
    Type: Application
    Filed: March 23, 2016
    Publication date: February 22, 2018
    Applicant: AJOU UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION
    Inventors: Yong Sung KIM, Ye Jin KIM
  • Publication number: 20180051065
    Abstract: The invention provides methods for producing a protein in a cell free protein synthesis system such that the protein does not contain an asparagine (Asn or N) residue at serine (Ser or S) positions. Also provided are compositions and nucleic acid templates for use in the methods described herein.
    Type: Application
    Filed: December 18, 2015
    Publication date: February 22, 2018
    Inventor: Gang Yin
  • Publication number: 20180051066
    Abstract: The present invention provides VEGF antagonists with improved pharmacokinetic properties. According to certain embodiments, a fusion polypeptide capable of antagonizing VEGF activity is provided comprising a modified extracellular ligand binding domain of a VEGF receptor fused to a multimerizing component.
    Type: Application
    Filed: June 16, 2017
    Publication date: February 22, 2018
    Inventors: Nicholas J. PAPADOPOULOS, Samuel DAVIS, George D. YANCOPOULOS
  • Publication number: 20180051067
    Abstract: The invention relates to a modified VWF molecule for use in the treatment of a blood coagulation disorder.
    Type: Application
    Filed: March 4, 2016
    Publication date: February 22, 2018
    Inventors: Michael MOSES, Stefan SCHULTE, Gerhard DICKNEITE, Uwe KALINA, Sabine PESTEL, Thomas WEIMER
  • Publication number: 20180051068
    Abstract: Embodiments disclosed herein relate to compositions comprising extracellular thaumatin domain proteins, or portions thereof (e.g., CalA polypeptides, or portions thereof), and compositions comprising binding agents (e.g., antibodies, fragments thereof, and the like) that bind specifically to CalA polypeptides, and methods of using the same for preventing or treating a fungal infection.
    Type: Application
    Filed: January 14, 2016
    Publication date: February 22, 2018
    Inventors: Scott Filler, Hong Liu, Norma Solis, Ashraf Ibrahim
  • Publication number: 20180051069
    Abstract: Compositions and methods are provided that relate to inhibiting and/or reducing glycosylation of IgE for the treatment of allergic and atopic disorders. These compositions and methods are based, in part, on the discovery that glycosylation of IgE is a requirement for initiation of the allergic cascade and that a single N-linked site in the C?3 domain of mouse and human IgE, occupied by an oligomannose structure, specifically N394 of the C?3 domain of human IgE is required for the conformational integrity of the IgE.
    Type: Application
    Filed: March 4, 2016
    Publication date: February 22, 2018
    Applicant: THE GENERAL HOSPITAL CORPORATION
    Inventors: Robert M. ANTHONY, Kai-Ting SHADE
  • Publication number: 20180051070
    Abstract: The present invention relates to a fusion proteins comprising regulatory T cell protein, VISTA (V-domain Immunoglobulin Suppressor of T cell Activation (PD-L3) and an immunoglobulin protein (Ig), preferably also containing a flexible linker intervening the VISTA and Ig Fc polypeptide. The invention also provides the use of VISTA polypeptides, multimeric VISTA polypeptides, VISTA-conjugates (e.g., VISTA-Ig), and VISTA antagonists for the treatment of autoimmune disease, allergy, and inflammatory conditions, especially lupus, multiple sclerosis, psoriasis, psoriatic arthritis, multiple sclerosis, Crohn's disease, inflammatory bowel disease and type 1 or type 2 diabetes.
    Type: Application
    Filed: April 18, 2016
    Publication date: February 22, 2018
    Inventors: Randolph J. Noelle, Sabrina Ceeraz, Isabelle LeMercier, Elizabeth Nowak, Janet Lines
  • Publication number: 20180051071
    Abstract: Provided is an antibody or an immunologically reactive fragment thereof which targets exclusively an A? having a specific turn structure of A? (a toxic conformer of A?). Also provided are a medicinal composition comprising, as an active ingredient, an antibody that specifically recognizes a toxic conformer of A?, a kit for assaying a toxic conformer of A?, a diagnostic agent for Alzheimer's disease, etc.
    Type: Application
    Filed: December 14, 2015
    Publication date: February 22, 2018
    Inventors: Kazuhiro Irie, Kazuma Murakami, Takahiko Shimizu, Naotaka Izuo, Tsutomu Seito
  • Publication number: 20180051072
    Abstract: The present invention relates, in part, to isolated antibodies that specifically interact with and show measurable binding affinity to an epitope of the amyloid-beta (A?) protein. Such antibodies may be used for the modulation of A? activity and/or aggregation or amyloidosis, to study the effects of the A? protein on cell function and, in certain embodiments, for the treatment and/or prevention of a disease or condition associated with A? activity, aggregation, and/or amyloidosis.
    Type: Application
    Filed: February 23, 2016
    Publication date: February 22, 2018
    Applicant: rPeptide LLC
    Inventors: Quentin FLORENCE, Nanda MENON, William MOFFITT, Bill LUNSFORD, III
  • Publication number: 20180051073
    Abstract: The present invention relates, in part, to isolated antibodies that specifically interact with and show measurable binding affinity to an epitope of the tau protein. Such antibodies may be used for the modulation of tau activity and/or aggregation, to study the effects of the tau protein on cell function and, in certain embodiments, for the treatment and/or prevention of a disease or condition associated with neurodegenerative tauopathy.
    Type: Application
    Filed: February 23, 2016
    Publication date: February 22, 2018
    Applicant: rPeptide LLC
    Inventors: Quentin FLORENCE, Nanda MENON, William MOFFITT, Bill LUNSFORD, III
  • Publication number: 20180051074
    Abstract: This disclosure provides a method for enhancing cell-mediated immunity in individuals with disorders such as cancer or infection that involves administering an inhibitor of GOLPH2 to the individuals. For example, inhibition of GOLPH2 increases the endogenous production of IL-12.
    Type: Application
    Filed: October 31, 2017
    Publication date: February 22, 2018
    Inventor: Xiaojing Ma
  • Publication number: 20180051075
    Abstract: The present invention provides methods of treating, preventing or delaying the onset of bone marrow failure in Fanconi Anemia patients comprising administering to the patient a composition comprising a neutralizing anti-TGF-beta antibody, e.g. fresolimumab or 1D11.
    Type: Application
    Filed: February 25, 2016
    Publication date: February 22, 2018
    Inventors: Alan D'ANDREA, Kalindi PARMAR, Haojian ZHANG
  • Publication number: 20180051076
    Abstract: The present invention is directed to novel Anti-TNF? antibody binding compounds and methods of using the same. Anti-TNF? antibody binding compounds of the invention comprise novel heavy chain immunoglobulin polypeptides of portions thereof. In some embodiments, the invention also includes pharmaceutical compositions comprising at least one Anti-TNF? antibody binding compound. The invention further provides the use of an Anti-TNF? antibody binding compound of the invention in the preparation of a medicament for the therapeutic and/or prophylactic treatment of a disorder.
    Type: Application
    Filed: March 14, 2016
    Publication date: February 22, 2018
    Inventors: Robert DuBridge, Veronica Juan
  • Publication number: 20180051077
    Abstract: The present invention relates to a pharmaceutical product for the treatment of a proliferative disease, comprising the combination of an antibody, or an antigen-binding portion thereof, that specifically binds to human CD40; and a PD-L1 antibody; and optionally a 3rd component which comprises as an active ingredient a cytokine inhibitor.
    Type: Application
    Filed: October 2, 2017
    Publication date: February 22, 2018
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Emily Rana Corse, Olivier Freytag, Christian Gerdes, Marine Le Clech, Hyam Levitsky, Marion OTT, Martin Stern, Wei Xu
  • Publication number: 20180051078
    Abstract: The present invention describes methods for treating inflammatory disorders of the gastrointestinal tract, including but not limited to Inflammatory Bowel Disease (IBD), Crohn's Disease (CD), Ulcerative Colitis (UC) and/or medically refractory ulcerative colitis (MR-UC) using anti-IFNG therapy. The present invention also describes a process for patient risk stratification.
    Type: Application
    Filed: March 15, 2016
    Publication date: February 22, 2018
    Applicant: Cedars-Sinai Medical Center
    Inventors: Stephan R. TARGAN, Janine BILSBOROUGH, Dermot P. MCGOVERN
  • Publication number: 20180051079
    Abstract: This invention relates to chimeric and humanized antibodies that specifically bind the BCR complex, and particularly chimeric and humanized antibodies to the BCR complex. The invention also relates to methods of using the antibodies and compositions comprising them in the diagnosis, prognosis and therapy of diseases such as cancer, autoimmune diseases, inflammatory disorders, and infectious disease.
    Type: Application
    Filed: May 31, 2017
    Publication date: February 22, 2018
    Applicant: MacroGenics, Inc.
    Inventors: Leslie S. Johnson, Ling Huang
  • Publication number: 20180051080
    Abstract: The present invention pertains to antigen recognizing constructs against COL6A3 antigens. The invention in particular provides novel T cell receptor (TCR) based molecules which are selective and specific for the tumor expressed antigen COL6A3. The TCR of the invention, and COL6A3 antigen binding fragments derived therefrom, are of use for the diagnosis, treatment and prevention of COL6A3 expressing cancerous diseases. Further provided are nucleic acids encoding the antigen recognizing constructs of the invention, vectors comprising these nucleic acids, recombinant cells expressing the antigen recognizing constructs and pharmaceutical compositions comprising the compounds of the invention.
    Type: Application
    Filed: August 15, 2017
    Publication date: February 22, 2018
    Inventors: Leonie ALTEN, Dominik MAURER, Steffen WALTER, Sebastian BUNK
  • Publication number: 20180051081
    Abstract: Provided are monoclonal antibodies and antigen-binding fragments thereof that bind to CD47 of multiple mammalian species, block the binding of SIRPalpha and TSP1 to CD47, promote phagocytosis of susceptible cancer cells, and reverse TSP1 inhibition of nitric oxide signaling, as well as monoclonal antibodies and antigen binding fragments thereof that compete with the former for binding to CD47 and that exhibit similar biological activities. Also provided are combinations of any of the foregoing. Such antibody compounds are variously effective in 1) treating tissue ischemia and ischemia-reperfusion injury (IRI) in the setting of organ preservation and transplantation, pulmonary hypertension, sickle cell disease, myocardial infarction, stroke, and other instances of surgery and/or trauma in which IRI is a component of pathogenesis; 2) in treating autoimmune and inflammatory diseases; and 3) as anti-cancer agents for treating susceptible cancer cells, promoting their phagocytic uptake and clearance.
    Type: Application
    Filed: October 3, 2017
    Publication date: February 22, 2018
    Inventors: William A. FRAZIER, Pamela T. MANNING, Gerhard FREY, Hwai Wen CHANG
  • Publication number: 20180051082
    Abstract: The invention relates to an isolated immunoglobulin heavy chain polypeptide and an isolated immunoglobulin light chain polypeptide that bind to a programmed death-1 (PD-1) protein. The invention provides a PD-1-binding agent that comprises the aforementioned immunoglobulin heavy chain polypeptide and immunoglobulin light chain polypeptide. The invention also provides related vectors, compositions, and methods of using the PD-1-binding agent to treat a cancer or an infectious disease.
    Type: Application
    Filed: October 5, 2017
    Publication date: February 22, 2018
    Inventors: David J. King, Marilyn Kehry
  • Publication number: 20180051083
    Abstract: Described herein are novel compositions comprising bispecific and multispecific polypeptide agents, and methods using these agents for targeting cells, such as functionally exhausted or unresponsive immune cells, that co-express the inhibitory receptors PD-1 and TIM-3. These compositions and methods are useful for the treatment of chronic immune conditions, such as persistent infections or cancer.
    Type: Application
    Filed: November 3, 2017
    Publication date: February 22, 2018
    Applicant: The Brigham and Women's Hospital, Inc.
    Inventors: Vijay K. KUCHROO, Ana C. ANDERSON
  • Publication number: 20180051084
    Abstract: Provided are methods for prophylaxis and/or therapy of cancer that include administering to an individual in need thereof an effective amount of a ?-blocker and an immune checkpoint inhibitor such that growth of cancer in the individual is inhibited. Patients include those diagnosed with or at risk for a wide variety of cancer types. Methods are provided for cancer treatment in individuals who are resistant to checkpoint inhibitor monotherapies. Greater than additive anti-cancer effects may be achieved.
    Type: Application
    Filed: March 14, 2016
    Publication date: February 22, 2018
    Inventors: Elizabeth REPASKY, Bonnie HYLANDER
  • Publication number: 20180051085
    Abstract: The present invention concerns compositions and methods of use of anti-PD-1 antibodies comprising CDR sequences corresponding to SEQ ID NO:1 to SEQ ID NO:6. Preferably the antibody is a humanized antibody comprising the variable region amino acid sequences of SEQ ID NO: 9 and SEQ ID NO:10. The antibodies are of use to treat cancer and may be administered alone or with another standard anti-cancer therapy. The methods may comprise administering the anti-PD-1 antibody or antigen-binding fragment thereof in combination with one or more therapeutic agents such as antibody-drug conjugates, interferons (preferably interferon-?), and/or other checkpoint inhibitor antibodies.
    Type: Application
    Filed: November 3, 2017
    Publication date: February 22, 2018
    Inventors: Chien-Hsing Chang, David M. Goldenberg
  • Publication number: 20180051086
    Abstract: Disclosed is a method for treating a subject having primary sclerosing cholangitis, comprising administering to said subject an effective amount of a humanized antibody or antigen-binding fragment thereof having binding specificity for alpha 4 beta 7 integrin.
    Type: Application
    Filed: March 4, 2016
    Publication date: February 22, 2018
    Applicants: Takeda Development Centre Europe Ltd., Takeda Pharmaceutical Company Limited, Millennium Pharmaceuticals, Inc.
    Inventor: Brihad ABHYANKAR
  • Publication number: 20180051087
    Abstract: This invention concerns anti-inflammatory agents, compositions, and methods for treating inflammatory disorders.
    Type: Application
    Filed: March 4, 2016
    Publication date: February 22, 2018
    Applicant: ROCKEFELLER UNIVERSITY (THE)
    Inventors: Jeffrey V. Ravetch, Andrew Pincetic
  • Publication number: 20180051088
    Abstract: The disclosure provides, among other aspects, neutralizing antibodies and portions thereof that bind to ActRIIB and uses for same.
    Type: Application
    Filed: April 3, 2017
    Publication date: February 22, 2018
    Inventors: Ravindra Kumar, Asya Grinberg, Monique Davies, Diana Martik, Janja Cosic, Rachel Kent, David Buckler
  • Publication number: 20180051089
    Abstract: The present invention relates to a TCR KO—or TCR KO and dCK KO—engineered immune cells expressing a Chimeric Antigen Receptors (CAR) specific for CD123 that is a recombinant chimeric protein able to redirect immune cell specificity and reactivity toward CD123-expressing cells, and more particularly in which extracellular ligand binding is a scFV derived from a CD123 monoclonal antibody, conferring specific immunity against CD123 positive cells. The engineered immune cells endowed with such CD123 CARs are particularly suited for treating relapse refractory AML and blastic plasmacytoid dendritic cell neoplasm and for use as a treatment before bone marrow transplantation.
    Type: Application
    Filed: January 25, 2016
    Publication date: February 22, 2018
    Inventors: Roman GALETTO, Barbara Johnson SASU, Arvind RAJPAL, Philippe DUCHATEAU, Alexandre JUILLERAT, Julien VALTON, Mathieu SIMON
  • Publication number: 20180051090
    Abstract: The present invention provides a method of cell culture comprising adding a cell-containing seed medium to an initial medium and starting to culture the cell in the initial medium, wherein the initial medium has an organism-derived culture medium additive added thereto and the amount of the C-terminal amidated species in the produced protein is controlled by the copper content of the initial medium at the start of cell culture.
    Type: Application
    Filed: March 25, 2016
    Publication date: February 22, 2018
    Applicant: Chugai Seiyaku Kabushiki Kaisha
    Inventors: Seiko YAMAMOTO, Hiroyuki DOI, Isamu TERASHIMA
  • Publication number: 20180051091
    Abstract: Antibody polypeptides that specifically bind human CD40L are provided. The antibody polypeptides do not activate platelets. The antibody polypeptides are useful in the treatment of diseases involving CD40L activation, such as graft-related diseases and autoimmune diseases. The antibody polypeptides may be domain antibodies (dAbs) comprising a single VH or VK domain. The half-life of the antibody polypeptides may be increased by modifying the antibody polypeptides to be dual specific reagents that can also bind human serum albumin (HSA) or another antigen.
    Type: Application
    Filed: August 3, 2017
    Publication date: February 22, 2018
    Inventors: Steven G. NADLER, James K. TAMURA, Laura PRICE, Robert P. REHFUSS, Suzanne J. SUCHARD, Anish SURI, James William BRYSON, Aaron YAMNIUK, Steven GRANT, Olga IGNATOVICH, Philip DREW
  • Publication number: 20180051092
    Abstract: Anti-BAFFR antibodies are formulated as liquid formulation comprising a high concentration of the antibody active ingredient for delivery to a patient without high levels of antibody aggregation. The aqueous pharmaceutical composition may include one or more sugars, a buffering agent, a surfactant, and/or a free amino acid.
    Type: Application
    Filed: August 31, 2017
    Publication date: February 22, 2018
    Inventors: Marta COSENZA, Christoph Stark
  • Publication number: 20180051093
    Abstract: The present invention relates to antibodies capable of binding to the coagulation Factor XI and/or its activated form factor XIa and methods of use thereof, particularly methods of use as agents inhibiting platelet aggregation and by this inhibits thrombus formation.
    Type: Application
    Filed: August 30, 2017
    Publication date: February 22, 2018
    Inventors: Andreas WILMEN, Julia STRAßBURGER, Frank DITTMER, Michael STRERATH, Anja BUCHMÜLLER, Joanna GRUDZINSKA-GOEBEL, Ricarda FINNERN, Martina SCHÄFER, Christoph GERDES, Hannah JÖRIßEN, Asako ITAKURA, Philberta Y. LEUNG, Erik TUCKER
  • Publication number: 20180051094
    Abstract: The invention relates to antibodies, and in particular, to antibodies used in the diagnosis and treatment of neurodegenerative disorders, such as Alzheimer's disease and Parkinson's disease. The invention extends to methods of diagnosis and therapy of neurodegenerative disorders, and to assays and screens for isolating novel therapeutic compounds for treating such diseases.
    Type: Application
    Filed: March 23, 2016
    Publication date: February 22, 2018
    Inventors: Susan Adele GREENFIELD, Sara GARCIA-RATES, Paul MORRILL
  • Publication number: 20180051095
    Abstract: The present invention provides a multivalent immunoglobulin or part thereof binding specifically to at least two cell surface molecules of a single cell with at least one modification in at least one structural loop region of said immunoglobulin determining binding to an epitope of said cell surface molecules wherein the unmodified immunoglobulin does not significantly bind to said epitope, its use and methods for producing it.
    Type: Application
    Filed: August 15, 2017
    Publication date: February 22, 2018
    Inventors: Florian RUKER, Gottfried HIMMLER, Gordana WOZNIAK-KNOPP
  • Publication number: 20180051096
    Abstract: The present invention relates to physically modified sago starch which exhibits an increased onset of gelatinization temperature and controlled viscosity development, yet retains significant hot and cold viscosity, the process of making such starch, and the use thereof. Such starches are useful in a variety of products, particularly as viscosifiers.
    Type: Application
    Filed: October 30, 2017
    Publication date: February 22, 2018
    Inventor: Tarak Shah
  • Publication number: 20180051097
    Abstract: Compositions and methods relating to fucan agents useful for the treatment, prevention, inhibition, etc., of fibrous adhesions or other diseases.
    Type: Application
    Filed: September 22, 2016
    Publication date: February 22, 2018
    Applicant: ARC Medical Devices, Inc.
    Inventor: Christopher Michael Kevin Springate
  • Publication number: 20180051098
    Abstract: A process and equipment assembly for reacting a substituent precursor with a cyclodextrin starting material to provide a raw product comprising a cyclodextrin derivative and 1% or less of an initial amount of the substituent precursor is provided. The process of the present invention provides cyclodextrin derivatives in substantially shorter time and with fewer side products than previous processes that utilize substantially the same starting materials.
    Type: Application
    Filed: August 31, 2017
    Publication date: February 22, 2018
    Inventors: Vincent D. Antle, Jose R. Matos
  • Publication number: 20180051099
    Abstract: Processes to prepare highly functional fiber products from agricultural by-products (e.g., sugar beet pulp, orange peel, apple pulp and other pectin containing agricultural processing by-products) and their applications are disclosed. Sequential extraction of pectin from agricultural by-products produced a series of fractions with excellent oil in water emulsification and water holding capacity properties.
    Type: Application
    Filed: August 18, 2016
    Publication date: February 22, 2018
    Inventors: Madhav P. Yadav, Arland T. Hotchkiss, Kyle Hanah, Madhuvanti Kale
  • Publication number: 20180051100
    Abstract: The present disclosure relates to hyaluronic acid derivatives, and in particular, derivatives in which the N-acetyl group of hyaluronic acid has been substituted, and methods and uses thereof.
    Type: Application
    Filed: May 4, 2017
    Publication date: February 22, 2018
    Inventor: Tassos Anastassiades
  • Publication number: 20180051101
    Abstract: A modified conjugated diene-based polymer is produced by reacting a conjugated diene-based polymer having an alkali metal or an alkali-earth metal at a terminal of the polymer with a compound represented by formula (1). R1 and R2 independently represent a hydrocarbyl group having 20 or fewer carbon atoms. R3 represents a substituted alkyl group having 20 or fewer carbon atoms prepared through substitution of at least one of a hydrogen atom and —CH2— of an alkyl group by a group containing only at least one heteroatom selected from the group consisting of nitrogen, phosphorus, oxygen, and sulfur, or a monovalent aromatic group having 20 or fewer carbon atoms and containing at least one element selected from the group consisting of nitrogen, phosphorus, oxygen, and sulfur, with the proviso that R3 does not have active hydrogen. R4 represents an alkanediyl group having 20 or fewer carbon atoms.
    Type: Application
    Filed: January 29, 2016
    Publication date: February 22, 2018
    Applicant: JSR CORPORATION
    Inventors: Takumi ADACHI, Koichiro TANI, Hiroyuki MORITA, Ryoji TANAKA
  • Publication number: 20180051102
    Abstract: The invention relates to a process for transitioning from a first continuous polymerization reaction in a reactor, for example a gas-phase reactor conducted in the presence of a first catalyst to a second continuous polymerization reaction in the react or conducted in the presence of a second catalyst, wherein the first and second catalysts are incompatible, the process comprising: (a) discontinuing the introduction of the first catalyst from a catalyst feeding system into a reactor and emptying the catalyst feeding system of the first catalyst; (b) introducing a first catalyst killer to the reactor to substantially deactivate the first catalyst in the reactor; (c) introducing a second catalyst killer to the catalyst feeding system to substantially deactivate the first catalyst in the catalyst feeding system; (d) introducing a second catalyst to the catalyst feeding system and (e) introducing the second catalyst to the reactor from the catalyst feeding system, wherein the second catalyst killer is the same as
    Type: Application
    Filed: March 24, 2016
    Publication date: February 22, 2018
    Inventor: Mohammed Althukair
  • Publication number: 20180051103
    Abstract: An oligomer production method and a catalyst, the method comprising a step of co-oligomerizing a polymerizable monomer including ethylene and an ?-olefin in the presence of a catalyst containing (A) a compound represented by a formula (1), (B) a compound represented by a formula (2), (C) methylaluminoxane and/or a boron compound and (D) an organozine compound and/or an organoaluminun compound other than methylaluminoxane, and an oligomer production method and a catalyst comprising a step of oligomerizing a polymerizable monomer including an olefin in the presence of a catalyst containing a complex of a ligand being a diimine compound represented by a formula (3) and a metal of Group 8 elements, etc.
    Type: Application
    Filed: March 16, 2016
    Publication date: February 22, 2018
    Applicant: JXTG NIPPON OIL & ENERGY CORPORATION
    Inventors: Fuyuki AIDA, Kazuo TAGAWA
  • Publication number: 20180051104
    Abstract: A fluorine-containing boric acid PVB composite comprising a condensate of a fluorine-containing alcohol, boric acid and polyvinyl butyral, wherein the fluorine-containing alcohol is represented by the general formula: Rf(A-OH)k wherein k is 1 or 2; when k is 1, Rf is a perfluoroalkyl group having 6 or less carbon atoms, a polyfluoroalkyl group in which some of the fluorine atom or atoms of the perfluoroalkyl group are replaced by hydrogen atom or atoms, a polyfluoroalkyl group containing a terminal perfluoroalkyl group having 6 or less carbon atoms and a perfluoroalkylene group having 6 or less carbon atoms, or a linear or branched, perfluoroalkyl group containing a terminal perfluoroalkyl group having 6 or less carbon atoms, a perfluoroalkylene group having 6 or less carbon atoms and ether bonds; when k is 2, Rf is a linear or branched, perfluoroalkylene group or polyfluoroalkylene group, containing a perfluoroalkylene group having 6 or less carbon atoms and ether bonds; and A is an alkylene group having
    Type: Application
    Filed: March 10, 2016
    Publication date: February 22, 2018
    Inventors: Takeshi FUKUSHIMA, Katsuyuki SATO, Hideo SAWADA
  • Publication number: 20180051105
    Abstract: Organosilicon compounds having a structure represented by the general formula and a method for using same are provided as electron donors in the Ziegler-Natta type catalyst system for the homo-polymerization or co-polymerization of alpha olefins. The organosilicon compounds may be used in the preparation of the solid catalyst component, thus serving as “internal electron donors”, or employed during or prior to polymerization as “external electron donors,” and therefore they can be used to prepare phthalate-free polyolefins.
    Type: Application
    Filed: April 19, 2017
    Publication date: February 22, 2018
    Inventors: Demin Xu, Guangxue Xu
  • Publication number: 20180051106
    Abstract: A solid catalyst component which exhibits high activity and stereospecificity in the polymerization of olefins made from or containing Mg, Ti and an electron donor of formula (I) where R and R1 are selected from the group consisting of C1-C20 hydrocarbon groups, C6-C14 aryl or alkylaryl groups hydrocarbon groups, optionally containing a heteroatom selected from the group consisting of halogens, P, S, N, and O; R2 to R11 groups, equal to or different from each other, are hydrogen, halogen or C1-C15 hydrocarbon groups which can be optionally fused together to form one or more cycles with the proviso that R6 and R11 cannot join together to form a phenyl ring.
    Type: Application
    Filed: March 8, 2016
    Publication date: February 22, 2018
    Applicant: BASELL POLIOLEFINE ITALIA S.R.L.
    Inventors: REYNALD CHEVALIER, ALESSANDRO MIGNOGNA, GIAMPIERO MORINI
  • Publication number: 20180051107
    Abstract: The present disclosure is directed to a construct for promoting absorption of molecules by a cell and the application thereof in drug and gene delivery. The present disclosure further describes topographical modulation of endocytosis for drug and gene delivery.
    Type: Application
    Filed: October 11, 2017
    Publication date: February 22, 2018
    Applicants: AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (A*STAR), NATIONAL UNIVERSITY OF SINGAPORE
    Inventors: King Fai Evelyn YIM, Hong Yee LOW, Tanu Suryadi KUSTANDI, Kim Kiat TEO, Seok Hong GOH
  • Publication number: 20180051108
    Abstract: Provided is a method of preparing polybutadiene which may improve productivity by minimizing a plugging phenomenon occurred during the preparation of polybutadiene and increasing a conversion rate.
    Type: Application
    Filed: October 18, 2016
    Publication date: February 22, 2018
    Applicant: LG Chem, Ltd.
    Inventors: Woo Sung Hwang, Jun Seok Ko, Hoi In Jeong, Jong Ku Lee
  • Publication number: 20180051109
    Abstract: A copolymer having a structural unit derived from a conjugated diene compound and a structural unit derived from an ?-olefin having 3 to 8 carbon atoms, wherein the copolymer has a melting point within a temperature range of 0 to 10° C. and has a fusion enthalpy of 5 J/g or more as measured on a differential scanning calorimeter under the following conditions. Conditions: (1) cooling from 200° C. to ?150° C. at a rate of 10° C./min; (2) retaining at ?150° C. for 1 minute; and (3) heating from ?150° C. to 200° C. at a rate of 20° C./min.
    Type: Application
    Filed: January 29, 2016
    Publication date: February 22, 2018
    Applicant: JSR CORPORATION
    Inventors: Takuo SONE, Shouichi MATSUMOTO, Ayumi WATANABE, Ayumi HARA
  • Publication number: 20180051110
    Abstract: A catalyst consisting essentially of at least one tertiary monophenyl amine having a formula R1R2N-aryl, where R1 and R2 are the same or different, and each is a hydrogen, an alkyl, or a cycloalkyl group, where at least one of R1 and R2 contain at least one carbon atom; at least one titanium halide having a formula TiXm, where m is from 2.5 to 4.0 and X is a halogen containing moiety; and at least one cocatalyst having a formula AlRn Y3-n where R is a hydrocarbon radical, Y is a halogen or hydrogen, and n is 1-3. Further, the catalyst is absent of a carrier or support.
    Type: Application
    Filed: October 12, 2017
    Publication date: February 22, 2018
    Applicants: Saudi Arabian Oil Company, King Fahd University of Petroleum & Minerals
    Inventors: Muhammad Atiqullah, Abdel Salam Al-Sarkhi, Faisal Mohammed Al-Thenayan, Abdullah Raddad Al-Malki, Wei Xu, Anwar Hossaen